Skip to content

US · ERAS · BIOTECHNOLOGY

Erasca, Inc. (ERAS) intrinsic value and stock valuation

$13.61as of 2026-11-21 · Mkt cap 6.39B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Erasca, Inc. DCF and intrinsic value

InvestorsCraft values ERAS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ERAS’s statements →

Erasca, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 erasca.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-124.55M
20192025
Free cash flow
-$-95.58M
20192025
Total equity
$325.2M+24.8% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-131.41M-$-179.59M-$-141.53M-$-247.45M-$-124.88M
Net income-$-124.55M-$-161.65M-$-125.04M-$-242.81M-$-122.76M
EPSd-$-439.28K-$-691.34K-$-832.6K-$-1.99M-$-1.03M
Operating cash flow-$-95.45M-$-109.42M-$-101.22M-$-103.26M-$-79.6M
Capital expenditure-$-130K-$-22.56M-$-1.77M-$-16.55M-$-18.89M
Free cash flow-$-95.58M-$-131.98M-$-102.99M-$-119.81M-$-98.48M
Total assets$396.2M$502.5M$395.3M$514.9M$501.4M
Total debt$47.1M$51.9M$55.9M$55.1M$18.8M
Net debt-$-26.67M-$-15.85M-$-37.22M-$-229.12M-$-341.7M
Total equity$325.2M$423.5M$316.7M$411.9M$456.5M
Cash and short-term investments$276.1M$298.3M$312.4M$435.6M$414.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$3.11M$0.00$3.73M$2.64M$830K
Gross profit-$-3.11M$0.00-$-3.73M-$-2.64M-$-830K
Research and development expenses$92.9M$115.4M$103.8M$112.5M$73.9M
Selling, general and administrative expenses$38.6M$41.7M$37.7M$33M$22.6M
Other expenses-$-3.11M$22.5M-$-3.73M$99.4M$27.5M
Operating expenses$128.3M$179.6M$137.8M$244.8M$124.1M
Cost and expenses$131.4M$179.6M$141.5M$247.5M$124.9M
Interest income$16.6M$20.1M$16.7M$4.9M$190K
Interest expense$0.00$0.00$0.00$201.4M$0.00
Depreciation and amortization$3.11M$3.81M$3.73M$2.64M$830K
Ebitda-$-121.44M-$-153.28M-$-121.31M-$-240.16M-$-121.94M
Operating income-$-131.41M-$-179.59M-$-141.53M-$-247.45M-$-124.88M
Total other income/expenses, net$6.86M$17.9M$16.5M$4.64M$2.12M
Income before tax-$-124.55M-$-161.65M-$-125.04M-$-242.81M-$-122.76M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-124.55M-$-161.65M-$-125.04M-$-242.81M-$-122.76M
Weighted average shares outstanding$283.5M$233.8M$150.2M$122M$119.1M
Weighted average diluted shares outstanding$283.5M$233.8M$150.2M$122M$119.1M
Balance sheet
20252024202320222021
Cash and short-term investments$276.1M$298.3M$312.4M$435.6M$414.5M
Net receivables$2.5M$2.3M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$286.2M$308.8M$320.7M$444.5M$420M
Property, plant and equipment, net$42.3M$48.5M$60.2M$65.2M$33.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$66.1M$142.2M$10.1M$2M$44.8M
Total non-current assets$109.9M$193.7M$74.6M$70.4M$81.4M
Total assets$396.2M$502.5M$395.3M$514.9M$501.4M
Accounts payable$980K$470K$2M$23.1M$4.68M
Short-term debt$5.07M$4.62M$3.97M$1.3M$280K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$28.5M$31.4M$26.2M$48.7M$26.2M
Long-term debt$42.1M$47.3M$51.9M$53.8M$18.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$42.5M$47.6M$52.5M$54.4M$18.7M
Capital lease obligations$47.1M$51.9M$55.9M$55.1M$18.8M
Total liabilities$71M$79M$78.6M$103.1M$44.9M
Common stock$30K$30K$10K$10K$10K
Retained earnings-$-892.21M-$-767.66M-$-606.01M-$-480.97M-$-238.17M
Accumulated other comprehensive income (loss)$630K$410K$80K-$-1.04M-$-160K
Total equity$325.2M$423.5M$316.7M$411.9M$456.5M
Total investments$268.4M$372.7M$229.3M$153.4M$98.8M
Total debt$47.1M$51.9M$55.9M$55.1M$18.8M
Net debt-$-26.67M-$-15.85M-$-37.22M-$-229.12M-$-341.7M
Cash flow statement
20252024202320222021
Net income-$-124.55M-$-161.65M-$-125.04M-$-242.81M-$-122.76M
Depreciation and amortization$3.11M$3.81M$3.73M$2.64M$830K
Stock-based compensation$24.9M$27M$26.2M$20.1M$8.33M
Change in working capital-$-3.33M$1.74M$810K$15.8M$7.71M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$510K-$-1.53M-$-890K$680K$1.34M
Net cash provided by operating activities-$-95.45M-$-109.42M-$-101.22M-$-103.26M-$-79.6M
Investments in property, plant and equipment-$-130K-$-60K-$-1.77M-$-16.55M-$-18.89M
Acquisitions, net$0.00$0.00$0.00$4M$7.68M
Net cash used for investing activities$100.4M-$-156.62M-$-91.22M-$-71.08M-$-64.59M
Common stock issued$1.1M$239.1M$1.29M$95.3M$317M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.1M$240.7M$1.29M$98.1M$439.4M
Net change in cash$6.07M-$-25.34M-$-191.14M-$-76.27M$295.2M
Cash at end of period$74.2M$68.2M$93.5M$284.6M$360.9M
Operating cash flow-$-95.45M-$-109.42M-$-101.22M-$-103.26M-$-79.6M
Capital expenditure-$-130K-$-22.56M-$-1.77M-$-16.55M-$-18.89M
Free cash flow-$-95.58M-$-131.98M-$-102.99M-$-119.81M-$-98.48M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Erasca, Inc.

        Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

        CEO
        Jonathan E. Lim
        Employees
        103
        Beta
        0.67

        Explore

        Frequently asked questions

        What is the intrinsic value of Erasca, Inc. (ERAS)?

        InvestorsCraft does not currently publish an intrinsic value for ERAS. How the IC value is calculated.

        Is ERAS undervalued?

        InvestorsCraft does not publish an undervaluation signal for ERAS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.